Adherence with oral oncologic treatment in cancer patients: Interest of an adherence score of all dosing errors

Oncology (Switzerland)

Volumn 84, Issue 2, 2012, Pages 67-74

  Thivat, E ^a,c,d,e   Van Praagh, I ^b   Belliere, A ^b,d,e   Mouret Reynier, M A ^b   Kwiatkowski, F ^a,d,e   Durando, X ^a,b,d,e,f   Mahammedi, H ^b,d,e   Dillies, A F ^b,d,e   Chollet, P ^a,b,d,e,f   Chevrier, R ^c,d  

^a Division of Clinical Research   (France)

^b Department of Oncology ^*  (France)

^c CENTRE JEAN PERRIN   (France)

^d Centre d'Investigation Clinique UMR 501   (France)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

^f INSERM   (France)

Author keywords

Adherence to medications; Cancer patient; Oral oncologic treatment

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; LAPATINIB; TAMOXIFEN; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; BREAST CANCER; BREAST CARCINOMA; CALCULATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG MONITORING; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; MASTECTOMY; MEGALOCYTOSIS; NAUSEA; ONCHOLYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MEDICATION ADHERENCE; MEDICATION ERRORS; MIDDLE AGED; PATIENT COMPLIANCE; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES;

EID: 84868228273     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342087     Document Type: Article

References (29)

1. Ruddy K, Mayer E, Partridge A: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59: 56-66.
2. Partridge AH, Wang PS, Winer EP, Avorn J: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21: 602-606.
3. Chlebowski RT, Geller ML: Adherence to endocrine therapy for breast cancer. Oncology 2006; 71: 1-9.
4. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008; 99: 1763-1768.
5. Partridge AH: Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006; 17: 183-184.
6. Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008; 26: 549-555.
7. Lash TL, Fox MP, Westrup JL, Fink AK, Sil-liman RA: Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006; 99: 215-220.
8. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ: Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007; 109: 832-839.
9. Levine AM, Richardson JL, Marks G, Chan K, Graham J, Selser JN, Kishbaugh C, Shel-ton DR, Johnson CA: Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987; 5: 1469-1476.
10. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR: Patient noncom-pliance with self-administered chemotherapy. Cancer 1990; 65: 17-22.
11. Lee CR, Nicholson PW, Souhami RL, Deshmukh AA: Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 1992; 10: 1007-1013.
12. Muss HB, Berry DA, Cirrincione CT, et al: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360: 2055-2065.
13. Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, Winer EP: Tol-erability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 2009; 117: 615-623.
14. Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H: Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010; 28: 2418-2422.
15. Waterhouse DM, Calzone KA, Mele C, Brenner DE: Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11: 1189-1197.
16. Ailinger RL, Black PL, Lima-Garcia N: Use of electronic monitoring in clinical nursing research. Clin Nurs Res 2008; 17: 89-97.
17. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 2005; 353: 487-497.
18. Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P: Adherence to adjuvant endocrine therapy in postmeno-pausal women with breast cancer. Ann Oncol 2009; 20: 431-436.
19. Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998; 4: 941-948.
20. Kwiatkowski F, Girard M, Hacene K, Berlie J: Sem: a suitable statistical software adaptated for research in oncology. Bull Cancer 2000; 87: 715-721.
21. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556-562.
22. Sedjo RL, Devine S: Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011; 125: 191-200.
23. Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U: Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 2011; 19: 1009-1018.
24. Decker V, Spoelstra S, Miezo E, Bremer R, You M, Given C, Given B: A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents. Cancer Nurs 2009; 32:E20-E29.
25. Hadji P: Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010; 73: 156-166.
26. Verma S, Madarnas Y, Sehdev S, Martin G, Bajcar J: Patient adherence to aromatase inhibitor treatment in the adjuvant setting. Curr Oncol 2011; 18:S3-S9.
27. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
28. Winterhalder R, Hoesli P, Delmore G, Pederiva S, Bressoud A, Hermann F, von Moos R: Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology 2011; 80: 29-33.
29. Koch KM, Reddy NJ, Cohen RB, Lewis NL, Whitehead B, Mackay K, Stead A, Beelen A P, Lewis LD: Effects of food on the relative bio-availability of lapatinib in cancer patients. J Clin Oncol 2009; 27: 1191-1196.